Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inovio, MedImmune partner under $45m DARPA Ebola contract

This article was originally published in Scrip

Executive Summary

Shares of Inovio Pharmaceuticals got a 8.6% boost on 8 April on the news the firm was named the prime contractor by the US Defense Advanced Research Projects Agency (DARPA) to lead a consortium of companies and academic researchers tapped to develop multiple treatment and prevention approaches against Ebola – a disease that has infected more than 25,500 people in the current outbreak in West Africa, killing over 10,500.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts